Comprehensive Financial Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Comprehensive Financial Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.46M	Hold	941,895	–	–	0.11%	22
2026 Q1	$2.89M	Hold	941,895	–	–	0.1%	21
2025 Q4	$3.85M	Hold	941,895	–	–	0.12%	19
2025 Q3	$4.6M	Hold	941,895	–	–	0.13%	17
2025 Q2	$4.77M	Hold	941,895	–	–	0.13%	18
2025 Q1	$4.98M	Hold	941,895	–	–	0.16%	15
2024 Q4	$6.37M	Hold	941,895	–	–	0.18%	15
2024 Q3	$6.21M	Hold	941,895	–	–	0.17%	17
2024 Q2	$7.06M	Hold	941,895	–	–	0.25%	15
2024 Q1	$9.39M	Hold	941,895	–	–	0.3%	12
2023 Q4	$9.29M	Hold	941,895	–	–	0.33%	13
2023 Q3	$7.21M	Sell	941,895 -167,500	-15%	-$1.67M	0.26%	14
2023 Q2	$8.29M	Hold	1,109,395	–	–	0.27%	13
2023 Q1	$7.4M	Hold	1,109,395	–	–	0.22%	13
2022 Q4	$8.55M	Hold	1,109,395	–	–	0.28%	11
2022 Q3	$11.8M	Hold	1,109,395	–	–	0.31%	12
2022 Q2	$9.03M	Hold	1,109,395	–	–	0.25%	15
2022 Q1	$7.94M	Hold	1,109,395	–	–	0.14%	16
2021 Q4	$19M	Hold	1,109,395	–	–	0.24%	13
2021 Q3	$25.5M	Hold	1,109,395	–	–	0.24%	12
2021 Q2	$40.5M	Buy	+1,109,395	New	+$32.8M	0.34%	10

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Comprehensive Financial Management's RXRX Position: Q2 2026 in Review

Comprehensive Financial Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 941,895 shares worth $3.46M. The position accounts for 0.11% of the portfolio, ranked #22.

Comprehensive Financial Management first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $40.5M in Q2 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Comprehensive Financial Management held 941,895 shares of Recursion Pharmaceuticals worth $3.46M as of Q2 2026.
Comprehensive Financial Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.11% of Comprehensive Financial Management's portfolio in Q2 2026, its #22 holding.
Comprehensive Financial Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
Comprehensive Financial Management's Recursion Pharmaceuticals position peaked at $40.5M in Q2 2021.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Comprehensive Financial Management's 13F filing for Q2 2026, filed 14 Aug 2026.